Shots:

• The P-ll CALAVI programme involves assessing Calquence + BSC vs BSC as monothx. in patients in a ratio (1:1) hospitalized with respiratory complications of COVID-19 in the ratio of 1:1. The trials conducted in the US and in multiple other countries across the world
• The CALAVI program did not meet its 1EPs of increasing the proportion of patients who remained alive and free of respiratory failure- safety and tolerability profiles were consistent with previous studies
• Calquence is selective inhibitor of BTK- binds covalently to BTK- thereby inhibiting its activity

­  Ref: AstraZeneca | Image: Red River Radio